Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
Type:
Grant
Filed:
August 22, 2019
Date of Patent:
July 4, 2023
Assignee:
Promega Corporation
Inventors:
Joel R. Walker, Thomas A. Kirkland, Wenhui Zhou, Mary P. Hall, Harry Tetsuo Uyeda
Abstract: The present invention provides reagents for instrumentation quality control and methods of use thereof. In particular, sets of peptides or other molecules are provided for evaluating the performance of instruments with mass spectrometry (MS) and/or liquid chromatography (LC) functionalities.
Type:
Grant
Filed:
January 27, 2021
Date of Patent:
July 4, 2023
Assignee:
Promega Corporation
Inventors:
Joshua Jacques Coon, Michael M. Rosenblatt, Marjeta Urh
Abstract: A polynucleotide encoding a modified luciferase polypeptide. The modified luciferase polypeptide has at least 60% amino acid sequence identity to a wild-type Oplophorus luciferase and includes at least one amino acid substitution at a position corresponding to an amino acid in a wild-type Oplophorus luciferase of SEQ ID NO: 1. The modified luciferase polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the wild-type Oplophorus luciferase.
Type:
Grant
Filed:
June 20, 2022
Date of Patent:
June 6, 2023
Assignee:
Promega Corporation
Inventors:
Lance P. Encell, Mary Hall, Paul Otto, Gediminas Vidugiris, Keith V. Wood, Monika G. Wood, Kristopher Zimmerman
Abstract: Provided herein are cell-permeable, cell-compatible, and chemoselectively-cleavable linkers for tethering (e.g., covalently) functional elements (e.g., a cellular interaction element and a capture element), and methods of use (e.g., intracellular capture and extracellular release of cellular targets) therewith.
Type:
Grant
Filed:
March 9, 2020
Date of Patent:
June 6, 2023
Assignee:
Promega Corporation
Inventors:
Sergiy Levin, Rachel Friedman Ohana, Thomas Kirkland, Keith V. Wood
Abstract: An isolated polynucleotide encoding a modified luciferase polypeptide and substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type Oplophorus luciferase.
Type:
Grant
Filed:
September 3, 2020
Date of Patent:
May 30, 2023
Assignee:
PROMEGA CORPORATION
Inventors:
Brock Binkowski, Lance P. Encell, Mary Hall, Matthew B. Robers, Michael R. Slater, Keith V. Wood, Monika G. Wood, Dieter Klaubert, Poncho Meisenheimer, James Unch, Michael P. Valley
Abstract: Disclosed are luciferase polypeptides with improved light-emitting activity and their encoding nucleic acids. These molecules are useful in a range of assays including luciferase-based gene reporter assays, bioluminescence resonance energy transfer assays, protein complementation assays and other applications in which luciferase enzymes are utilized as detectable and/or quantifiable labels. Also disclosed are methods and compositions for increasing the sensitivity and/or improving the kinetics of luciferase-catalyzed reactions as well as decreasing the impact of undesirable variables.
Type:
Grant
Filed:
August 12, 2019
Date of Patent:
May 30, 2023
Assignee:
Promega Corporation
Inventors:
John Michael Daly, Leon Michael Brownrigg, Jim Yu-Hsiang Tiao
Abstract: Compounds that may inhibit Oplophorus-derived luciferases are disclosed as well as compositions and kits comprising the compounds and methods of using the compounds.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
May 23, 2023
Assignee:
Promega Corporation
Inventors:
Brock Binkowski, Mary P. Hall, Thomas Machleidt, Joel Walker, Wenhui Zhou
Abstract: The invention provides surfactant compounds of formulas I-IX, which can be used in methods for aiding the solubilization, digestion, preparation, analysis, and/or characterization of biological material, for example, proteins or cell membranes. The compounds can also aid in the recovery of peptides generated during protein digestion, particularly for in-gel digestion protocol. Additionally, the compounds can improve enzymatic protein deglycosylation without interfering with downstream sample preparation steps and mass spectrometric analysis. The compounds can be specifically useful as digestion aids that can be decomposed by an acid, by heat, or a combination thereof. Decomposition of the surfactants allows for facile separation from isolated samples, and/or allows for analysis of the sample without interfering with the sensitivity of various analytical techniques.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
April 11, 2023
Assignee:
Promega Corporation
Inventors:
Sergei Saveliev, Daniel Simpson, Keith V. Wood, Harry Tetsuo Uyeda, Carolyn Woodroofe Hitko, Dieter Klaubert
Abstract: Provided herein are systems and methods for characterizing target/ligand engagement. In particular, luciferase-labeled polypeptide targets are used to detect or quantify target/ligand engagement (e.g., within a cell or cell lysate).
Type:
Grant
Filed:
November 25, 2020
Date of Patent:
January 31, 2023
Assignee:
Promega Corporation
Inventors:
Melanie Dart, Lance P. Encell, Thomas Kirkland, Thomas Machleidt, Matthew Robers, Brock F. Binkowski, Keith Wood, Ce Shi
Abstract: Provided herein are compositions and methods for stabilizing coelenterazine and analogs or derivatives thereof, and for improving the solubility and reconstitution efficiency of coelenterazine and analogs and derivatives thereof.
Type:
Grant
Filed:
October 3, 2019
Date of Patent:
December 27, 2022
Assignee:
Promega Corporation
Inventors:
Melanie Dart, Thomas Smith, Thomas Kirkland, Thomas Machleidt, Keith Wood
Abstract: The present disclosure includes compositions and methods for improved DNA amplification reactions. In particular, the present disclosure provides compositions and methods for hot-start PCR applications using DNA polymerase inhibitors that minimize non-specific DNA amplification by inactivating DNA polymerase at lower temperatures.
Type:
Grant
Filed:
December 12, 2019
Date of Patent:
December 13, 2022
Assignee:
Promega Corporation
Inventors:
Wenhui Zhou, Kimberly K. Knoche, Douglas R. Storts, Min Zhou, Poncho Meisenheimer
Abstract: Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
November 8, 2022
Assignee:
Promega Corporation
Inventors:
Andrew S. Dixon, Lance Encell, Mary Hall, Keith Wood, Monika Wood, Marie Schwinn, Brock F. Binkowski, Hicham Zegzouti, Nidhi Nath, Subhanjan Mondal, Said Goueli, Poncho Meisenheimer, Thomas Kirkland, James Unch, Dileep K. Pulukkunat, Matthew Robers, Melanie Dart, Thomas Machleidt
Abstract: Provided herein are compounds that are broad-spectrum protein kinase binding agents, detectable tracers comprising such compounds, and method of use thereof for the detection of protein kinases.
Type:
Grant
Filed:
May 30, 2019
Date of Patent:
September 13, 2022
Assignee:
Promega Corporation
Inventors:
Cesear Corona, Poncho Meisenheimer, Matthew Robers, James Vasta
Abstract: Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT® bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
July 19, 2022
Assignee:
Promega Corporation
Inventors:
Joel R. Walker, Mary Hall, Christopher Todd Eggers, Horacio Lazaro
Abstract: A polynucleotide encoding a modified luciferase polypeptide. The modified luciferase polypeptide has at least 60% amino acid sequence identity to a wild-type Oplophorus luciferase and includes at least one amino acid substitution at a position corresponding to an amino acid in a wild-type Oplophorus luciferase of SEQ ID NO:1. The modified luciferase polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the wild-type Oplophorus luciferase.
Type:
Grant
Filed:
October 20, 2020
Date of Patent:
June 21, 2022
Assignee:
Promega Corporation
Inventors:
Lance P. Encell, Mary Hall, Paul Otto, Gediminas Vidugiris, Keith V. Wood, Monika G. Wood, Kristopher Zimmerman
Abstract: Provided herein are substantially non-luminescent peptide/polypeptide tags that are inserted internally within a protein of interest or between N-terminal and C-terminal peptides/polypeptides. Interaction of the internally-inserted tag with a complement polypeptide/peptide that is also substantially non-luminescent results in the formation a bioluminescent reporter complex.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
June 21, 2022
Assignee:
Promega Corporation
Inventors:
Andrew S. Dixon, Lance P. Encell, Thomas Machleidt, Marie Schwinn, Keith Wood, Monika Wood, Kris Zimmerman
Abstract: Provided herein are isolated polynucleotide encoding modified click beetle luciferase polypeptides that have enhanced luminescence and longer wavelength near-infrared signals. The disclosure also relates to near-infrared bioluminescence systems that include said modified click beetle luciferase polypeptides and novel luciferin derivatives, as well as methods of using said modified click beetle luciferase polypeptides and bioluminescence systems.
Type:
Grant
Filed:
December 23, 2019
Date of Patent:
April 5, 2022
Assignee:
Promega Corporation
Inventors:
Lance P. Encell, Mary P. Hall, Keith V. Wood, Monika G. Wood
Abstract: Provided herein are systems, methods, and compounds for identifying RAS binding compounds using a RAS binding agent, which comprises a RAS binding moiety and a functional element. In some embodiments, the RAS binding agent binds to one site on the RAS protein (e.g., KRAS, HRAS, or NRAS), and can be used to detect RAS binding agents that bind to the same site as well as other sites.
Type:
Application
Filed:
August 27, 2021
Publication date:
March 3, 2022
Applicant:
Promega Corporation
Inventors:
Matthew B. Robers, Joel R. Walker, James Vasta, Cesear Corona
Abstract: Provided herein are inhibitor-resistant luciferase mutants, and methods of use thereof. In particular, luciferase mutants are provided that are thermal stable and exhibit improved stability in the presence of luciferin break-down products, such as dehydroluciferin. Further provided are assay systems comprising inhibitor-resistant luciferase mutants and amino acid sequences of the inhibitor-resistant luciferase mutants.
Type:
Grant
Filed:
October 13, 2017
Date of Patent:
March 1, 2022
Assignee:
Promega Corporation
Inventors:
Ce Shi, Thomas Kirkland, Poncho Meisenheimer, Lance P. Encell, Mary Hall
Abstract: Methods, kits and compositions containing a mixture of D-luciferin and L-luciferin for light generation with luciferase are disclosed that have improved stability when stored over time. The mixture of D-luciferin and L-luciferin can be used to detect the presence or amount of ATP or of luciferase in a sample.
Type:
Grant
Filed:
November 1, 2019
Date of Patent:
January 4, 2022
Assignee:
PROMEGA CORPORATION
Inventors:
Michael P. Valley, James J. Cali, Brock Binkowski, Christopher Todd Eggers, Keith V. Wood